阿德福韦酯联合胸腺肽a1治疗HBeAg阳性慢性乙型肝炎的疗效观察

Effect of adefovir combined with thymopeptides a1 in treatment of patients with chronic hepatitis B of positive HBeAg

目的探讨阿德福韦酯（ADV）与胸腺肽a1联合治疗慢性乙型肝炎（CHB）抗乙肝病毒（HBV）的疗效。方法67例HBeAg阳性CHB患者分成联用组和单用组。联用组34例，联用ADV及胸腺肽a1治疗26周，随后继续单用ADV至52周。单用组33例，单用ADV治疗52周。定期检测丙氨酸氨基转氨酶（ALT）、总胆红素（TBil）、HBVDNA、HBeAg、抗-HBe，两组在治疗结束时进行疗效评价。结果两组治疗后肝功能（ACT、TBil）均有明显改善，两组间差异元统计学意义（均P〉0．05），联用组HBeAg／抗-HBe血清转换率41．2％、HBVDNA阴转率67．6％均明显高于单用组（均P〈0．05）。结论ADV联用胸腺肽a1治疗HBeAg阳性CHB疗效优于单用ADV。显示ADV与胸腺肽a1联用能增强抗HBV的效力，有助于病毒的清除。

Objective To explore the effects of adefovir velocimeter（ADV） combined with Thymopeptides a1 in treatment of patients with chronic hepatitis B （CHB） against hepatitis B virus （HBV）. Methods 67 cases of CHB of positive HBeAg were divided into coupling group and single group. 34 cases of coupling group, after being treated for 26 weeks with thymopeptides a1 and ADV, continued to be treated 52 weeks with ADV. 33 cases of single group were treated for 52 weeks with ADV alone. Alanine aminotransferase periodically （ALT）, total bilirubin, HBV DNA, HBeAg, anti-HBe were detected at regular intervals. Efficacy were evaluated after finishing the treatment. Results The liver function were both improved obviously in two groups （ P 〉 0.05 ）. Frequencen of seroeonversio of HBeAg/anti-HBe and negative conversion ratio of HBV DNA were much higher in coupling group than that in single group（P 〈 0.05 ）. Conclusions The effects were better with Thymopeptides a1 and ADV than that with single ADV. Couphng Thymopeptides a1 and ADV could help to resist and remove HBV.